CRLBF
Price
$0.98
Change
-$0.02 (-2.00%)
Updated
Aug 15 closing price
Capitalization
341.12M
82 days until earnings call
GRUSF
Price
$0.45
Change
-$0.01 (-2.17%)
Updated
Aug 15 closing price
Capitalization
108.88M
Interact to see
Advertisement

CRLBF vs GRUSF

Header iconCRLBF vs GRUSF Comparison
Open Charts CRLBF vs GRUSFBanner chart's image
Cresco Labs
Price$0.98
Change-$0.02 (-2.00%)
Volume$2.42M
Capitalization341.12M
Grown Rogue International
Price$0.45
Change-$0.01 (-2.17%)
Volume$182.13K
Capitalization108.88M
CRLBF vs GRUSF Comparison Chart in %
Loading...
CRLBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRUSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRLBF vs. GRUSF commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRLBF is a Hold and GRUSF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (CRLBF: $0.98 vs. GRUSF: $0.45)
Brand notoriety: CRLBF and GRUSF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CRLBF: 234% vs. GRUSF: 81%
Market capitalization -- CRLBF: $341.12M vs. GRUSF: $108.88M
CRLBF [@Pharmaceuticals: Generic] is valued at $341.12M. GRUSF’s [@Pharmaceuticals: Generic] market capitalization is $108.88M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.74B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRLBF’s FA Score shows that 0 FA rating(s) are green whileGRUSF’s FA Score has 0 green FA rating(s).

  • CRLBF’s FA Score: 0 green, 5 red.
  • GRUSF’s FA Score: 0 green, 5 red.
According to our system of comparison, GRUSF is a better buy in the long-term than CRLBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRLBF’s TA Score shows that 5 TA indicator(s) are bullish while GRUSF’s TA Score has 6 bullish TA indicator(s).

  • CRLBF’s TA Score: 5 bullish, 4 bearish.
  • GRUSF’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, GRUSF is a better buy in the short-term than CRLBF.

Price Growth

CRLBF (@Pharmaceuticals: Generic) experienced а +31.61% price change this week, while GRUSF (@Pharmaceuticals: Generic) price change was +11.76% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Reported Earning Dates

CRLBF is expected to report earnings on Nov 07, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRLBF($341M) has a higher market cap than GRUSF($109M). CRLBF YTD gains are higher at: 7.537 vs. GRUSF (-31.831). CRLBF has more cash in the bank: 155M vs. GRUSF (5.59M). GRUSF has less debt than CRLBF: GRUSF (8.27M) vs CRLBF (646M).
CRLBFGRUSFCRLBF / GRUSF
Capitalization341M109M313%
EBITDA95.7MN/A-
Gain YTD7.537-31.831-24%
P/E RatioN/A22.31-
Revenue706MN/A-
Total Cash155M5.59M2,772%
Total Debt646M8.27M7,811%
FUNDAMENTALS RATINGS
CRLBF vs GRUSF: Fundamental Ratings
CRLBF
GRUSF
OUTLOOK RATING
1..100
2026
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
10057
SMR RATING
1..100
9545
PRICE GROWTH RATING
1..100
3758
P/E GROWTH RATING
1..100
10062
SEASONALITY SCORE
1..100
46n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GRUSF's Valuation (63) in the null industry is in the same range as CRLBF (76). This means that GRUSF’s stock grew similarly to CRLBF’s over the last 12 months.

GRUSF's Profit vs Risk Rating (57) in the null industry is somewhat better than the same rating for CRLBF (100). This means that GRUSF’s stock grew somewhat faster than CRLBF’s over the last 12 months.

GRUSF's SMR Rating (45) in the null industry is somewhat better than the same rating for CRLBF (95). This means that GRUSF’s stock grew somewhat faster than CRLBF’s over the last 12 months.

CRLBF's Price Growth Rating (37) in the null industry is in the same range as GRUSF (58). This means that CRLBF’s stock grew similarly to GRUSF’s over the last 12 months.

GRUSF's P/E Growth Rating (62) in the null industry is somewhat better than the same rating for CRLBF (100). This means that GRUSF’s stock grew somewhat faster than CRLBF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRLBFGRUSF
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
85%
MACD
ODDS (%)
N/A
Bullish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 5 days ago
83%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
70%
Aroon
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
CRLBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRUSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SIEPX14.500.05
+0.35%
Saratoga International Equity I
FSIDX17.75N/A
N/A
Fidelity Advisor Strategic Div & Inc I
NFJEX10.69N/A
N/A
Virtus NFJ Dividend Value Inst
ERLVX26.70-0.09
-0.34%
Eaton Vance Large-Cap Value R6
TAGFX11.35-0.06
-0.53%
Transamerica Mid Cap Growth R6

CRLBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRLBF has been closely correlated with TCNNF. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRLBF jumps, then TCNNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRLBF
1D Price
Change %
CRLBF100%
-1.25%
TCNNF - CRLBF
75%
Closely correlated
-7.35%
TSNDF - CRLBF
75%
Closely correlated
+1.10%
CURLF - CRLBF
73%
Closely correlated
-9.48%
VRNOF - CRLBF
72%
Closely correlated
-19.33%
GTBIF - CRLBF
71%
Closely correlated
-12.40%
More

GRUSF and

Correlation & Price change

A.I.dvisor tells us that GRUSF and GLASF have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GRUSF and GLASF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRUSF
1D Price
Change %
GRUSF100%
-3.00%
GLASF - GRUSF
32%
Poorly correlated
-6.40%
CRLBF - GRUSF
29%
Poorly correlated
-1.25%
CURLF - GRUSF
28%
Poorly correlated
-9.48%
TSNDF - GRUSF
27%
Poorly correlated
+1.10%
CXXIF - GRUSF
25%
Poorly correlated
-20.33%
More